These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 7679835)

  • 1. Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients.
    Porayko MK; Textor SC; Krom RA; Hay JE; Gores GJ; Wahlstrom HE; Sanchez-Urdazpal L; Richards T; Crotty P; Beaver S
    Transplant Proc; 1993 Feb; 25(1 Pt 1):665-8. PubMed ID: 7679835
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation: preliminary results from US Multicenter trial. U.S. Multicenter Liver Study Group.
    Porayko MK; Gonwa TA; Klintmalm GB; Wiesner RH
    Transplant Proc; 1995 Feb; 27(1):1114-6. PubMed ID: 7533358
    [No Abstract]   [Full Text] [Related]  

  • 3. Cyclosporine kinetics in pediatric liver transplant recipients: impact of dose fractionation on true glomerular filtration rate.
    Paradis K; al Edreesi M; St-Vil D; Laberge JM; Dupuis C; Rasquin-Weber A
    Transplant Proc; 1994 Oct; 26(5):2777-8. PubMed ID: 7940875
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of cyclosporine dosing on creatinine levels in hepatic transplant recipients.
    Gross CR; Savik SK; Ascher NL; Gordon RD; Klintmalm GB; Payne W; Shaw BW; Strasburg K; Parker A; Wiesner RH
    Transplant Proc; 1994 Oct; 26(5):2686-90. PubMed ID: 7940841
    [No Abstract]   [Full Text] [Related]  

  • 5. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation.
    Porayko MK; Textor SC; Krom RA; Hay JE; Gores GJ; Richards TM; Crotty PH; Beaver SJ; Steers JL; Wiesner RH
    Mayo Clin Proc; 1994 Feb; 69(2):105-11. PubMed ID: 7508536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection.
    Sandborn WJ; Hay JE; Porayko MK; Gores GJ; Steers JL; Krom RA; Wiesner RH
    Hepatology; 1994 Apr; 19(4):925-32. PubMed ID: 8138267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection.
    Woodle ES; So S; Jendrisak MD; Perdrizet GA; White HM; Marsh JW
    Transplant Proc; 1993 Apr; 25(2):1988-9. PubMed ID: 7682358
    [No Abstract]   [Full Text] [Related]  

  • 8. FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease.
    Woodle ES; Perdrizet GA; So S; Jendrisak MD; White HM; Marsh JW
    Transplant Proc; 1993 Apr; 25(2):1992-3. PubMed ID: 7682360
    [No Abstract]   [Full Text] [Related]  

  • 9. Renal function and tubular phosphate handling in long-term cyclosporine- and tacrolimus-based immunosuppression in kidney transplantation.
    Falkiewicz K; Kamińska D; Nahaczewska W; Boratyńska M; Owczarek H; Klinger M; Woźniak M; Patrzałek D; Szyber P
    Transplant Proc; 2006; 38(1):119-22. PubMed ID: 16504680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.
    Bismuth H
    Transplant Proc; 1995 Feb; 27(1):45-9. PubMed ID: 7533415
    [No Abstract]   [Full Text] [Related]  

  • 11. Renal function in liver transplant patients receiving FK506 or cyclosporin A immunosuppressive therapy.
    Frei U; Wagner K
    Transplant Proc; 1994 Dec; 26(6):3270-1. PubMed ID: 7527963
    [No Abstract]   [Full Text] [Related]  

  • 12. FK 506 rescue therapy: early conversion improves efficacy.
    Woodle ES; Perdrizet GA; So S; Jendrisak MD; White HM; Marsh JW
    Transplant Proc; 1993 Apr; 25(2):1990-1. PubMed ID: 7682359
    [No Abstract]   [Full Text] [Related]  

  • 13. Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection.
    Wiesner RH; Porayko MK; Wahlstrom HE; Gores GJ; Kamath PS; Hay JE; Krom RA
    Transplant Proc; 1993 Apr; 25(2):1791-3. PubMed ID: 7682352
    [No Abstract]   [Full Text] [Related]  

  • 14. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients.
    Winkler M; Jost U; Ringe B; Gubernatis G; Wonigeit K; Pichlmayr R
    Transplant Proc; 1991 Dec; 23(6):3153-5. PubMed ID: 1721389
    [No Abstract]   [Full Text] [Related]  

  • 16. Standard sequential immunosuppression with Minnesota antilymphoblast globulin and cyclosporine vs FK 506: a comparison of early nephrotoxicity.
    Stock PG; Ascher NL; Osorio RW; Tomlanovich S; Lake JR; Nikolai B; Freise C; Roberts JP
    Transplant Proc; 1993 Feb; 25(1 Pt 1):675-6. PubMed ID: 7679838
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term renal function in heart transplant recipients receiving cyclosporine therapy.
    Goral S; Ynares C; Shyr Y; Yeoh TK; Johnson HK
    J Heart Lung Transplant; 1997 Nov; 16(11):1106-12. PubMed ID: 9402509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurotoxicity of FK 506 in liver transplant recipients.
    Frank B; Perdrizet GA; White HM; Marsh JW; Lemann W; Woodle ES
    Transplant Proc; 1993 Apr; 25(2):1887-8. PubMed ID: 7682355
    [No Abstract]   [Full Text] [Related]  

  • 19. Conversion from standard cyclosporine to low-dose cyclosporine and azathioprine therapy as treatment for cyclosporine-related complications in liver transplant patients.
    Perkins JD; Sterioff S; Wiesner RH; Offord KP; Rakela J; Dickson ER; Krom RA
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2434-6. PubMed ID: 3274533
    [No Abstract]   [Full Text] [Related]  

  • 20. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression.
    Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J
    J Hepatol; 2006 Apr; 44(4):717-22. PubMed ID: 16487616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.